
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

SCHEDULE 13G

**Under the Securities Exchange Act of 1934
(Amendment No. 1)**

CULLINAN ONCOLOGY, INC.

(Name of Issuer)

**Common Stock, \$0.0001 par value
(Title of Class of Securities)**

**230031106
(CUSIP Number)**

**December 31, 2022
(Date of Event Which Requires Filing of this Statement)**

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

- Rule 13d-1(b)
- Rule 13d-1(c)
- Rule 13d-1(d)

* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

1	NAME OF REPORTING PERSON Globeways Holdings Ltd.	
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) (a) <input type="checkbox"/> (b) <input checked="" type="checkbox"/>	
3	SEC USE ONLY	
4	CITIZENSHIP OR PLACE OF ORGANIZATION British Virgin Islands	
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	5	SOLE VOTING POWER 0
	6	SHARED VOTING POWER 1,577,440 ⁽¹⁾
	7	SOLE DISPOSITIVE POWER 0
	8	SHARED DISPOSITIVE POWER 1,577,440 ⁽¹⁾
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 1,577,440 ⁽¹⁾	
10	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) <input type="checkbox"/>	
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 3.4% ⁽³⁾	
12	TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) PN	

⁽¹⁾ Includes (i) 491,715 shares of Common Stock held directly by Globeways Holdings Ltd., (ii) 537,392 shares of Common Stock held by F2 Bioscience I 2017 Ltd. and (iii) 548,333 shares of Common Stock held by F2 MG Ltd. Globeways Holdings Ltd. is the appointed manager of and has sole power to vote upon the acquisition, holding and disposal of all shares held by each of F2 Bioscience I 2017 Ltd. and F2 MG Ltd.

⁽²⁾ Percentage based on 45,772,452 shares of Common Stock outstanding as of November 4, 2022, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 14, 2022.

1	NAME OF REPORTING PERSON F2 Bioscience I 2017 Ltd.	
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) (a) <input type="checkbox"/> (b) <input checked="" type="checkbox"/>	
3	SEC USE ONLY	
4	CITIZENSHIP OR PLACE OF ORGANIZATION British Virgin Islands	
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	5	SOLE VOTING POWER 0
	6	SHARED VOTING POWER 537,392 ⁽¹⁾
	7	SOLE DISPOSITIVE POWER 0
	8	SHARED DISPOSITIVE POWER 537,392 ⁽¹⁾
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 537,392 ⁽¹⁾	
10	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) <input type="checkbox"/>	
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 1.2% ⁽²⁾	
12	TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) PN	

⁽¹⁾ The reported securities are owned directly by F2 Bioscience I 2017 Ltd. Globeways Holdings Ltd. is the appointed manager of F2 Bioscience I 2017 Ltd. and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Bioscience I 2017 Ltd.

⁽²⁾ Percentage based on 45,772,452 shares of Common Stock outstanding as of November 4, 2022, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 14, 2022.

1	NAME OF REPORTING PERSON F2 MG Ltd.	
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) (a) <input type="checkbox"/> (b) <input checked="" type="checkbox"/>	
3	SEC USE ONLY	
4	CITIZENSHIP OR PLACE OF ORGANIZATION British Virgin Islands	
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	5	SOLE VOTING POWER 0
	6	SHARED VOTING POWER 548,333 ⁽¹⁾
	7	SOLE DISPOSITIVE POWER 0
	8	SHARED DISPOSITIVE POWER 548,333 ⁽¹⁾
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 548,333 ⁽¹⁾	
10	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) <input type="checkbox"/>	
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 1.2% ⁽²⁾	
12	TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) PN	

⁽¹⁾ The reported securities are owned directly by F2 MG Ltd. Globeways Holdings Ltd. is the appointed manager of F2 MG Ltd. and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 MG Ltd.

⁽²⁾ Percentage based on 45,772,452 shares of Common Stock outstanding as of November 4, 2022, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 14, 2022.

1	NAME OF REPORTING PERSON Globeways Holdings II Ltd.	
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) (a) <input type="checkbox"/> (b) <input checked="" type="checkbox"/>	
3	SEC USE ONLY	
4	CITIZENSHIP OR PLACE OF ORGANIZATION British Virgin Islands	
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	5	SOLE VOTING POWER 0
	6	SHARED VOTING POWER 1,013,334 ⁽¹⁾
	7	SOLE DISPOSITIVE POWER 0
	8	SHARED DISPOSITIVE POWER 1,013,334 ⁽¹⁾
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 1,013,334 ⁽¹⁾	
10	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) <input type="checkbox"/>	
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 2.2% ⁽²⁾	
12	TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) PN	

⁽¹⁾ Includes (i) 622,175 shares of Common Stock held by F2-TPO Investments, LLC, (ii) 71,599 shares of Common Stock held by F2 Bio TD, LLC, (iii) 214,798 shares of Common Stock held by F2 MC, LLC, and (iv) 104,762 shares of Common Stock held by F2 GC, LLC. Globeways Holdings II Ltd. is the appointed manager of and has sole power to vote upon the acquisition, holding and disposal of all shares held by each of F2-TPO Investments, LLC, F2 Bio TD, LLC, F2 MC, LLC and F2 GC, LLC.

⁽²⁾ Percentage based on 45,772,452 shares of Common Stock outstanding as of November 4, 2022, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 14, 2022.

1	NAME OF REPORTING PERSON F2-TPO Investments, LLC	
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) (a) <input type="checkbox"/> (b) <input checked="" type="checkbox"/>	
3	SEC USE ONLY	
4	CITIZENSHIP OR PLACE OF ORGANIZATION Delaware	
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	5	SOLE VOTING POWER 0
	6	SHARED VOTING POWER 622,175 ⁽¹⁾
	7	SOLE DISPOSITIVE POWER 0
	8	SHARED DISPOSITIVE POWER 622,175 ⁽¹⁾
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 622,175 ⁽¹⁾	
10	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) <input type="checkbox"/>	
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 1.4% ⁽²⁾	
12	TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) OO	

⁽¹⁾ The reported securities are owned directly by F2-TPO Investments, LLC. Globeways Holdings II Ltd. is the appointed manager of F2-TPO Investments, LLC and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2-TPO Investments, LLC.

⁽²⁾ Percentage based on 45,772,452 shares of Common Stock outstanding as of November 4, 2022, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 14, 2022.

1	NAME OF REPORTING PERSON F2 Bio TD, LLC	
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) (a) <input type="checkbox"/> (b) <input checked="" type="checkbox"/>	
3	SEC USE ONLY	
4	CITIZENSHIP OR PLACE OF ORGANIZATION Delaware	
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	5	SOLE VOTING POWER 0
	6	SHARED VOTING POWER 71,599 ⁽¹⁾
	7	SOLE DISPOSITIVE POWER 0
	8	SHARED DISPOSITIVE POWER 71,599 ⁽¹⁾
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 71,599 ⁽¹⁾	
10	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) <input type="checkbox"/>	
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 0.2% ⁽²⁾	
12	TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) OO	

⁽¹⁾ The reported securities are owned directly by F2 Bio TD, LLC. Globeways Holdings Ltd. is the appointed manager of F2 Bio TD, LLC and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Bio TD, LLC.

⁽²⁾ Percentage based on 45,772,452 shares of Common Stock outstanding as of November 4, 2022, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 14, 2022.

1	NAME OF REPORTING PERSON F2 MC, LLC	
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) (a) <input type="checkbox"/> (b) <input checked="" type="checkbox"/>	
3	SEC USE ONLY	
4	CITIZENSHIP OR PLACE OF ORGANIZATION Delaware	
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	5	SOLE VOTING POWER 0
	6	SHARED VOTING POWER 214,798 ⁽¹⁾
	7	SOLE DISPOSITIVE POWER 0
	8	SHARED DISPOSITIVE POWER 214,798 ⁽¹⁾
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 214,798 ⁽¹⁾	
10	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) <input type="checkbox"/>	
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 0.5% ⁽²⁾	
12	TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) OO	

⁽¹⁾ The reported securities are owned directly by F2 MC, LLC. Globeways Holdings II Ltd. is the appointed manager of F2 MC, LLC. and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 MC, LLC.

⁽²⁾ Percentage based on 45,772,452 shares of Common Stock outstanding as of November 4, 2022, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 14, 2022.

1	NAME OF REPORTING PERSON F2 GC, LLC	
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) (a) <input type="checkbox"/> (b) <input checked="" type="checkbox"/>	
3	SEC USE ONLY	
4	CITIZENSHIP OR PLACE OF ORGANIZATION Delaware	
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	5	SOLE VOTING POWER 0
	6	SHARED VOTING POWER 104,762 ⁽¹⁾
	7	SOLE DISPOSITIVE POWER 0
	8	SHARED DISPOSITIVE POWER 104,762 ⁽¹⁾
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 104,762 ⁽¹⁾	
10	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) <input type="checkbox"/>	
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 0.2% ⁽²⁾	
12	TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) OO	

⁽¹⁾ The reported securities are owned directly by F2 GC, LLC. Globeways Holdings II Ltd. is the appointed manager of F2 GC, LLC. and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 GC, LLC.

⁽²⁾ Percentage based on 45,772,452 shares of Common Stock outstanding as of November 4, 2022, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 14, 2022.

1	NAME OF REPORTING PERSON F2 Vision Management Sarl	
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) (a) <input type="checkbox"/> (b) <input checked="" type="checkbox"/>	
3	SEC USE ONLY	
4	CITIZENSHIP OR PLACE OF ORGANIZATION Luxembourg	
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	5	SOLE VOTING POWER 0
	6	SHARED VOTING POWER 985,394 ⁽¹⁾
	7	SOLE DISPOSITIVE POWER 0
	8	SHARED DISPOSITIVE POWER 985,394 ⁽¹⁾
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 985,394 ⁽¹⁾	
10	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) <input type="checkbox"/>	
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 2.2% ⁽²⁾	
12	TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) CO	

⁽¹⁾ Includes 985,394 shares of Common Stock held by F2 Vision SCS. F2 Vision Management Sarl is the appointed manager of and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Vision SCS.

⁽²⁾ Percentage based on 45,772,452 shares of Common Stock outstanding as of November 4, 2022, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 14, 2022.

1	NAME OF REPORTING PERSON F2 Vision SCS	
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) (a) <input type="checkbox"/> (b) <input checked="" type="checkbox"/>	
3	SEC USE ONLY	
4	CITIZENSHIP OR PLACE OF ORGANIZATION Luxembourg	
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	5	SOLE VOTING POWER 0
	6	SHARED VOTING POWER 985,394 ⁽¹⁾
	7	SOLE DISPOSITIVE POWER 0
	8	SHARED DISPOSITIVE POWER 985,394 ⁽¹⁾
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 985,394 ⁽¹⁾	
10	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) <input type="checkbox"/>	
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 2.2% ⁽²⁾	
12	TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) PN	

⁽¹⁾ The reported securities are owned directly by F2 Vision SCS. F2 Vision Management Sarl is the appointed manager of and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Vision SCS.

⁽²⁾ Percentage based on 45,772,452 shares of Common Stock outstanding as of November 4, 2022, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 14, 2022.

1	NAME OF REPORTING PERSON Morana Jovan-Embiricos	
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) (a) <input type="checkbox"/> (b) <input checked="" type="checkbox"/>	
3	SEC USE ONLY	
4	CITIZENSHIP OR PLACE OF ORGANIZATION United Kingdom	
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	5	SOLE VOTING POWER 207,803 ⁽¹⁾
	6	SHARED VOTING POWER 3,576,168 ⁽²⁾⁽³⁾⁽⁴⁾
	7	SOLE DISPOSITIVE POWER 207,803 ⁽¹⁾
	8	SHARED DISPOSITIVE POWER 3,576,168 ⁽²⁾⁽³⁾⁽⁴⁾
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 3,783,971 ⁽¹⁾⁽²⁾⁽³⁾⁽⁴⁾	
10	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) <input type="checkbox"/>	
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 8.3% ⁽⁵⁾	
12	TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) IN	

⁽¹⁾ Includes 207,803 shares of Common Stock directly held by Dr. Morana Jovan-Embiricos.

⁽²⁾ Includes (i) 491,715 shares of Common Stock held directly by Globeways Holdings Ltd., (ii) 537,392 shares of Common Stock held by F2 Bioscience I 2017 Ltd. and (iii) 548,333 shares of Common Stock held by F2 MG Ltd. Globeways Holdings Ltd. is the appointed manager of and has sole power to vote upon the acquisition, holding and disposal of all shares held by each of F2 Bioscience I 2017 Ltd. and F2 MG Ltd. Dr. Morana Jovan-Embiricos is the founding director and shareholder of Globeways Holdings Ltd. and has the sole power to vote upon the acquisition, holding and disposal of all shares held by Globeways Holdings Ltd.

⁽³⁾ Includes (i) 622,175 shares of Common Stock held by F2-TPO Investments, LLC, (ii) 71,599 shares of Common Stock held by F2 Bio TD, LLC, (iii) 214,798 shares of Common Stock held by F2 MC, LLC, and (iv) 104,762 shares of Common Stock held by F2 GC, LLC. Globeways Holdings II Ltd. is the appointed manager of and has sole power to vote upon the acquisition, holding and disposal of all shares held by each of F2-TPO Investments, LLC, F2 Bio TD, LLC, F2 MC, LLC and F2 GC, LLC. Dr. Morana Jovan-Embiricos is the founding director and shareholder of Globeways Holdings II Ltd. and has the sole power to vote upon the acquisition, holding and disposal of all shares held by Globeways Holdings II Ltd.

⁽⁴⁾ Includes 985,394 shares of Common Stock held by F2 Vision SCS. F2 Vision Management Sarl is the appointed manager of and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Vision SCS. Dr. Morana Jovan-Embiricos is the founding director F2 Vision Management Sarl and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Vision Management Sarl.

⁽⁵⁾ Percentage based on 45,772,452 shares of Common Stock outstanding as of November 4, 2022, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 14, 2022.

Item 1.

- (a) Name of Issuer
Cullinan Oncology, Inc.
- (b) Address of Issuer's Principal Executive Offices
One Main Street, Suite 1350
Cambridge, MA 02142

Item 2.

- (a) Names of Persons Filing
Globeways Holdings Ltd.
F2 Bioscience I 2017 Ltd.
F2 MG Ltd.
Globeways Holdings II Ltd.
F2-TPO Investments, LLC
F2 Bio TD, LLC
F2 MC, LLC
F2 GC, LLC
F2 Vision Management Sarl
F2 Vision SCS
Morana Jovan-Embiricos
- (b) Address of Principal Business office or, if None, Residence
Globeways Holdings Ltd.
c/o LJ Management (Suisse) SA
7 Rue de la Confederation
Geneva 1204
Switzerland

F2 Bioscience I 2017 Ltd.
c/o LJ Management (Suisse) SA
7 Rue de la Confederation
Geneva 1204
Switzerland

F2 MG Ltd.
c/o GISEV (Suisse) SA
Contrada di Sassello 2
6900 Lugano
Switzerland

Globeways Holdings II Ltd.
c/o LJ Management (Suisse) SA
7 Rue de la Confederation
Geneva 1204
Switzerland
-

F2-TPO Investments, LLC
c/o Twin Focus
75 Park Plaza
Boston
Massachusetts 02116
USA

F2 Bio TD, LLC
c/o Twin Focus
75 Park Plaza
Boston
Massachusetts 02116
USA

F2 MC, LLC
c/o Twin Focus
75 Park Plaza
Boston
Massachusetts 02116
USA

F2 GC, LLC
c/o Twin Focus
75 Park Plaza
Boston
Massachusetts 02116
USA

F2 Vision Management Sarl
c/o Atalux
74 Grand-Rue
Luxembourg V8 L-1660

F2 Vision SCS
c/o Atalux
74 Grand-Rue
Luxembourg V8 L-1660

Morana Jovan-Embiricos
c/o LJ Management (Suisse) SA
7 Rue de la Confederation
Geneva 1204
Switzerland

(c)	Citizenship	
	Globeways Holdings Ltd.	British Virgin Islands
	F2 Bioscience I 2017 Ltd.	British Virgin Islands
	F2 MG Ltd.	British Virgin Islands
	Globeways Holdings II Ltd.	British Virgin Islands
	F2-TPO Investments, LLC	Delaware
	F2 Bio TD, LLC	Delaware
	F2 MC, LLC	Delaware
	F2 GC, LLC	Delaware
	F2 Vision Management Sarl	Luxembourg
	F2 Vision SCS	Luxembourg
	Morana Jovan-Embiricos	United Kingdom
(d)	Title of Class of Securities	
	Common Stock, par value \$0.0001 per share	
(e)	CUSIP Number	
	230031106	

Item 3. If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

- (a) Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
- (b) Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
- (c) Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
- (d) Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
- (e) An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
- (f) An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
- (g) A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
- (h) A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
- (i) A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
- (j) A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J);
- (k) Group, in accordance with § 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:

Item 4. Ownership.

(a) and (b) Amount beneficially owned:

- (i) F2 Bioscience I 2017 Ltd. directly owns 537,392 shares of Common Stock, which represents approximately 1.2% of the outstanding shares of Common Stock.
 - (ii) F2 MG Ltd. directly owns 548,333 shares of Common Stock, which represents approximately 1.2% of the outstanding shares of Common Stock.
 - (iii) F2-TPO Investments, LLC directly owns 622,175 shares of Common Stock, which represents approximately 1.4% of the outstanding shares of Common Stock.
 - (iv) F2 Bio TD, LLC directly owns 71,599 shares of Common Stock, which represents approximately 0.2% of the outstanding Common Stock.
 - (v) F2 MC, LLC directly owns 214,798 shares of Common Stock, which represents approximately 0.5% of the outstanding shares of Common Stock.
 - (vi) F2 GC, LLC directly owns 104,762 shares of Common Stock, which represents approximately 0.2% of the outstanding shares of Common Stock.
 - (vii) F2 Vision SCS directly owns 985,394 shares of Common Stock, which represents approximately 2.2% of the outstanding shares of Common Stock.
-

- (viii) Globeways Holdings Ltd. is the appointed manager of and has sole power to vote upon the acquisition, holding and disposal of all shares of Common Stock held by F2 Bioscience I 2017 Ltd. and F2 MG Ltd. In addition, Globeways Holdings Ltd. directly owns 491,715 shares of Common Stock. Thus, Globeways Holdings Ltd. may be deemed to beneficially own 1,577,440 shares of Common Stock, which represents approximately 3.4% of the outstanding shares of Common Stock.
- (ix) Globeways Holdings II Ltd. is the appointed manager of and has sole power to vote upon the acquisition, holding and disposal of all shares of Common Stock held by F2-TPO Investments, LLC, F2 Bio TD, LLC, F2 MC, LLC and F2 GC, LLC. Thus, Globeways Holdings II Ltd. may be deemed to beneficially own 1,013,334 shares of Common Stock, which represents approximately 2.2% of the outstanding shares of Common Stock.
- (x) F2 Vision Management Sarl is the appointed manager of and has sole power to vote upon the acquisition, holding and disposal of all shares of Common Stock held by F2 Vision SCS. Thus, F2 Vision Management Sarl may be deemed to beneficially own 985,394 shares of Common Stock, which represents approximately 2.2% of the outstanding shares of Common Stock.
- (xi) Dr. Morana Jovan-Embiricos is the founding director and shareholder of Globeways Holdings Ltd., Globeways Holdings II Ltd. and F2 Vision Management Sarl, and has the sole power to vote upon the acquisition, holding and disposal of all shares held by Globeways Holdings Ltd., Globeways Holdings II Ltd. and F2 Vision Management Sarl. In addition, Dr. Jovan-Embiricos directly holds 207,803 shares of Common Stock. Thus, Dr. Jovan-Embiricos may be deemed to beneficially own 3,783,971 shares of Common Stock, which represents approximately 8.3% of the outstanding shares of Common Stock.

(c) Number of shares as to which such person has:

Reporting Person	Number of Shares of Common Stock			
	(i)	(ii)	(iii)	(iv)
F2 Bioscience I 2017 Ltd.	0	537,392	0	537,392
F2 MG Ltd.	0	548,333	0	548,333
F2-TPO Investments, LLC	0	622,175	0	622,175
F2 Bio TD, LLC	0	71,599	0	71,599
F2 MC, LLC	0	214,798	0	214,798
F2 GC, LLC	0	104,762	0	104,762
F2 Vision SCS	0	985,394	0	985,394
Globeways Holdings Ltd.	0	1,577,440	0	1,577,440
Globeways Holdings II Ltd.	0	1,013,334	0	1,013,334
F2 Vision Management Sarl	0	985,394	0	985,394
Morana Jovan-Embiricos	207,803	3,576,168	207,803	3,576,168

- (i) Sole power to vote or direct the vote
(ii) Shared power to vote or to direct the vote
(iii) Sole power to dispose or to direct the disposition of
(iv) Shared power to dispose or to direct the disposition of

Percentage based on 45,772,452 shares of Common Stock outstanding as of November 4, 2022, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 14, 2022.

Item 5. Ownership of Five Percent or Less of a Class.

If this statement is being filed to report the fact that as of the date hereof the reporting persons have ceased to be the beneficial owner of more than five percent of the class of securities, check the following.

Item 6. Ownership of More than Five Percent on Behalf of Another Person.

N/A.

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.

N/A

Item 8. Identification and Classification of Members of the Group.

N/A

Item 9. Notice of Dissolution of Group.

N/A

Item 10. Certifications.

N/A

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: February 15, 2023

GLOBEWAYS HOLDINGS LTD.

By: /s/ Morana Jovan-Embiricos
Name: Morana Jovan-Embiricos
Title: Director

F2 BIOSCIENCE I 2017 LTD.

By: /s/ Rachel Hingham and Ivan Belford
Names: Rachel Hingham and Ivan Belford
Titles: Directors

F2 MG LTD.

By: /s/ Achille Gregory Severgnini
Names: Achille Gregory Severgnini
Titles: Director

GLOBEWAYS HOLDINGS II LTD.

By: /s/ Morana Jovan-Embiricos
Name: Morana Jovan-Embiricos
Title: Director

F2-TPO INVESTMENTS LLC

By: /s/ Morana Jovan-Embiricos
Name: Morana Jovan-Embiricos
Title: Director

F2 BIO TD, LLC

By: /s/ Morana Jovan-Embiricos
Name: Morana Jovan-Embiricos
Title: Director

F2 MC, LLC

By: /s/ Morana Jovan-Embiricos
Name: Morana Jovan-Embiricos
Title: Director

F2 GC, LLC

By: /s/ Morana Jovan-Embiricos
Name: Morana Jovan-Embiricos
Title: Director

F2 VISION MANAGEMENT SARL

By: /s/ Alain Renard and Christian Francois
Names: Alain Renard and Christian Francois
Titles: Directors

F2 VISION SCS

By: /s/ Alain Renard and Christian Francois
Names: Alain Renard and Christian Francois
Titles: Directors

/s/ Morana Jovan-Embiricos
Morana Jovan-Embiricos
